Stifel is bullish on CentralNic Group PLC (AIM:CNIC) - described as a ‘picks and shovels’ company for the digital age – with a repeat of a ‘buy’ rating pitched with a 286p price target, suggesting more than 100% upside to the current price.
CentralNic this morning told investors that organic growth further accelerated during the fourth quarter of 2021, following the company’s significant investment programme. The company, in a statement, highlighted year-on-year organic revenue growth of 37% for the twelve months ended December 31.
Stock pickers could be richly rewarded in the oil and gas sector – that’s the view of analysts at Berenberg.
Exploration and production shares, on average, are set for some 10% upside to their current levels, the investment bank said, whilst certain opportunities are seen to have much more potential.
Poolbeg Pharma has in-licensed a late, preclinical-stage, potentially broad-spectrum treatment for respiratory virus infections.
This latest deal represents the second in-licensing from an academic source and comes only six months after the company was founded, says Robin Davison at Proactive Research.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said its liquid biopsy system could offer an alternative to traditional tissue biopsy to assess the spread and mutation of metastatic breast cancer.
The company described research by the University of Southern California Norris Cancer Center that compared the two approaches as ‘ground-breaking’.
Genflow Biosciences PLC got off to a positive start as it began life as a London-listed company, making it the first longevity-focused biotech ever to float in Europe.
The shares were issued at a price of 8p in an oversubscribed placing to raise £3.7mln as part of the initial public offering (IPO), giving the company a market cap of £23.4mln.
CentralNic Group PLC (AIM:CNIC) told investors that organic growth further accelerated during the fourth quarter of 2021, following the company’s significant investment programme.
The company, in a statement, highlighted year-on-year organic revenue growth of 37% for the twelve months ended December 31.
Poolbeg Pharma PLC (AIM:POLB) said it has in-licensed a potential immunotherapy for respiratory virus infections such as influenza and coronavirus from the University of Warwick.
The RNA-based drug works by triggering nasal cells into an antiviral state to protect from the infecting virus.
Iofina PLC (AIM:IOF, OTC:IOFNF) described the outlook for 2022 as “encouraging” following strong demand for its iodine in the fourth quarter of 2021 and a 25% jump in iodine spot prices compared with October last year.
These trends are expected to continue through the first half of 2022, the company said in a statement.
Roquefort Therapeutics PLC (LSE:ROQ) said its LYRAMID research and development subsidiary has identified lead compounds that it will take forward for lab-based experiments to test their efficacy in altering cancer cell properties.
It added that further work is currently being carried out to gather more data on the ability of these candidate drugs to modify midkine expression.
Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF) said it added three million measured and indicated ounces of gold to its resource inventory in 2021, exceeding a target of 2.5mln ounces.
An additional 900,000 was added in the inferred category, mainly at the Ity project.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) said it is on track for a February spud at the Merlin-2 well on Alaska’s Nort Slope.
Commissioning of the Arctic Fox drill rig is underway prior to mobilisaton and construction works for the ice road have begun.
SEED Innovations Ltd noted the update by its portfolio company Yooma Wellness Inc that Boots will be stocking its MYO Plant Nutrition brand in over 800 stores. SEED has a holding of approximately 4.4% in Yooma.
Ed McDermott, SEED’s chief executive, said: “Boots is a major market leader in the UK health and beauty industry and we hope that this new relationship will create further shareholder value."
Shares in NQ Minerals PLC (AQSE:NQMI, OTCQB:NQMLF) were withdrawn from the Aquis Exchange today. A detailed update on the administration process is expected in March
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said it has appointed Dr Michael Kauffman to its board of directors as an independent non-executive director with immediate effect. He brings more than 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development, and regulatory strategy - currently serving on the boards of Karyopharm Therapeutics, which he founded, along with Verastem Oncology, Kezar Life Sciences and Adicet Bio. Chairman Iain Ross said Kauffman "brings a wealth of expertise in oncology drug development, having been instrumental in the approval of several oncology therapeutics".
BATM Advanced Communications Ltd (LSE:BVC, OTC:BTAVF) released statement on its ongoing discussions with FTSE Russell concerning its index nationality review, saying it remains committed to maintaining its membership of the FTSE UK Index series and continues to investigate the available options for achieving this objective. BATM anticipates that this process will require a further 15 months.
Chesnara PLC said that non-executive director Veronica Oak is retiring today having completed nine years in the job.
Plant Health Care PLC announced that its chief executive officer Dr Christopher Richards and chief operating officer Jeffrey Tweedy will provide a live presentation to update investors via the Investor Meet Company platform on the afternoon of 1 February, the day the company intends to release a trading statement platform.
Faron Pharmaceuticals Ltd said that CEO Dr Markku Jalkanen will participate in the Redeye Fight Cancer - Outlook 2022 Seminar on January 20. Jalkanen will provide a presentation on Faron and participate in a panel discussion focused on the future of immuno-oncology.